To test whether a skeletal muscle targeted gene therapy can rescue LPL deficiency, a mouse model that more closely mimics the human phenotype with hypertriglyceridemia and decreased LPL blood activity is needed. The gene discussed is LPL; the disease is hypertriglyceridemia.